|
Ki-1+ Anaplastic Large Cell Lymphoma
|
0.600 |
AlteredExpression
|
disease |
LHGDN |
This study suggested that CD26 is selectively expressed on ALK-positive, but not on ALK-negative, ALCL and HL.
|
17071493 |
2006 |
|
Ki-1+ Anaplastic Large Cell Lymphoma
|
0.600 |
Biomarker
|
disease |
LHGDN |
Activation of Rac1 and the exchange factor Vav3 are involved in NPM-ALK signaling in anaplastic large cell lymphomas.
|
17998938 |
2008 |
|
Ki-1+ Anaplastic Large Cell Lymphoma
|
0.600 |
AlteredExpression
|
disease |
LHGDN |
Loss of SHP1 enhances JAK3/STAT3 signaling and decreases proteosome degradation of JAK3 and NPM-ALK in ALK+ anaplastic large-cell lymphoma.
|
16825495 |
2006 |
|
Ki-1+ Anaplastic Large Cell Lymphoma
|
0.600 |
AlteredExpression
|
disease |
LHGDN |
We further evaluated the relationship between TIMP1 expression and STAT3 activation in 43 ALCL tumors (19 ALK(+) and 24 ALK(-)) using immunohistochemistry and a tissue microarray.
|
15161657 |
2004 |
|
Ki-1+ Anaplastic Large Cell Lymphoma
|
0.600 |
GeneticVariation
|
disease |
LHGDN |
Our study led to the detection of the CLTC-ALK fusion in an ALCL case and to the identification of two novel fusion partners of ALK: ALO17 (KIAA1618), a gene with unknown function, which was fused to ALK in an ALCL case with a t(2;17)(p23;q25), and CARS, encoding the cysteinyl-tRNA synthetase, which was fused to ALK in an IMT case with a t(2;11;2)(p23;p15;q31).
|
12112524 |
2002 |
|
Ki-1+ Anaplastic Large Cell Lymphoma
|
0.600 |
AlteredExpression
|
disease |
LHGDN |
This prognostic effect was strongly related to anaplastic lymphoma kinase (ALK) status: ALK-positive ALCL had significantly higher levels of active caspase 3, while high expression of the antiapoptotic proteins Bcl-2 and PI9 was almost completely restricted to ALK-negative cases.
|
12036886 |
2002 |
|
Ki-1+ Anaplastic Large Cell Lymphoma
|
0.600 |
AlteredExpression
|
disease |
LHGDN |
The molecular signature of ALK- ALCL included overexpression of CCR7, CNTFR, IL22, and IL21 genes but did not provide any obvious clues to the molecular mechanism underlying this tumor subtype.
|
17077326 |
2007 |
|
Ki-1+ Anaplastic Large Cell Lymphoma
|
0.600 |
Biomarker
|
disease |
LHGDN |
Non-muscle myosin heavy chain (MYH9): a new partner fused to ALK in anaplastic large cell lymphoma.
|
12800156 |
2003 |
|
Ki-1+ Anaplastic Large Cell Lymphoma
|
0.600 |
AlteredExpression
|
disease |
LHGDN |
In conclusion, we report the constitutive expression of C/EBPbeta in ALK-positive ALCL and show its relationship to NPM-ALK.
|
16709933 |
2006 |
|
Ki-1+ Anaplastic Large Cell Lymphoma
|
0.600 |
CausalMutation
|
disease |
CGI |
|
|
|
|
Ki-1+ Anaplastic Large Cell Lymphoma
|
0.600 |
Biomarker
|
disease |
CTD_human |
LY293111 inhibited proliferation of both ALK(+) and ALK(-) ALCL cell in a dose-dependent fashion and induced complete G(1)-S cell cycle arrest, which was accompanied by upregulation of p27 and downregulation of cyclin E. Pretreatment with LY293111 for 4 h resulted in profound inhibition of serum-induced phosphorylation of extracellular-regulated kinases-1 and 2 and Akt and a concomitant increase in the phosphorylation of the stress-activated kinase c-jun N-terminal kinases (JNK).
|
16151469 |
2005 |
|
Ki-1+ Anaplastic Large Cell Lymphoma
|
0.600 |
Biomarker
|
disease |
CTD_human |
Aberrant expression of the transcriptional factor Twist1 promotes invasiveness in ALK-positive anaplastic large cell lymphoma.
|
22155737 |
2012 |
|
Ki-1+ Anaplastic Large Cell Lymphoma
|
0.600 |
Biomarker
|
disease |
CTD_human |
Crizotinib in anaplastic large-cell lymphoma.
|
21345110 |
2011 |
|
Ki-1+ Anaplastic Large Cell Lymphoma
|
0.600 |
Biomarker
|
disease |
CTD_human |
Reactive oxygen species and lipoxygenases regulate the oncogenicity of NPM-ALK-positive anaplastic large cell lymphomas.
|
19503098 |
2009 |
|
Ki-1+ Anaplastic Large Cell Lymphoma
|
0.600 |
Biomarker
|
disease |
CTD_human |
Targeting ALK: a promising strategy for the treatment of non-small cell lung cancer, non-Hodgkin's lymphoma, and neuroblastoma.
|
22968692 |
2012 |
|
Ki-1+ Anaplastic Large Cell Lymphoma
|
0.600 |
Biomarker
|
disease |
CTD_human |
Chromosomal translocations and single point mutations involving the Anaplastic Lymphoma Kinase (ALK) gene have been described in several human tumors, including anaplastic large cell lymphoma (ALCL), non-small cell lung cancer (NCSLC), inflammatory myofibroblastic tumor (IMT) and neuroblastoma.
|
22920921 |
2012 |
|
Ki-1+ Anaplastic Large Cell Lymphoma
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
During the last year the expression of anaplastic lymphoma kinase clarified presentation and provided clues toward the outcome of anaplastic large cell lymphoma; the breakpoints of t(2;5) were mapped; constitutive activation of anaplastic lymphoma kinase by a chromosomal inversion was described; transformation was shown to be independent of nuclear localization of anaplastic lymphoma kinase; and phospholipase C-gamma was identified as a molecular target for the kinase activity of anaplastic lymphoma kinase.
|
10505771 |
1999 |
|
Ki-1+ Anaplastic Large Cell Lymphoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
We present a case of anaplastic lymphoma kinase (ALK)+ skin-limited ALCL that highlights this challenge and draws attention to pitfalls in assessing ALK status.
|
25404214 |
2015 |
|
Ki-1+ Anaplastic Large Cell Lymphoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
ALK was first reported in 1994 as a translocation in anaplastic large cell lymphoma and then described with different abnormalities in a number of tumors.
|
28112990 |
2017 |
|
Ki-1+ Anaplastic Large Cell Lymphoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
Most ALK positive cases of ALCL harbor the t(2;5) translocation that leads to expression of Nucleophosmin-Anaplastic Lymphoma Kinase (NPM-ALK).
|
25961698 |
2015 |
|
Ki-1+ Anaplastic Large Cell Lymphoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
We evaluated the incidence of ALCL, clinical characteristics, survival status, and outcome of crizotinib use in four relapsed/refractory ALK-positive patients.
|
29150811 |
2018 |
|
Ki-1+ Anaplastic Large Cell Lymphoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
ALCL-negative tumours had a significantly worse prognosis than ALK-positive.
|
18275429 |
2008 |
|
Ki-1+ Anaplastic Large Cell Lymphoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
Difficulties with classification of lymphomas are also encountered, such as the distinction of classical Hodgkin's lymphoma from anaplastic large-cell lymphoma that is negative for anaplastic lymphoma kinase.
|
20227918 |
2010 |
|
Ki-1+ Anaplastic Large Cell Lymphoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
In this study, we investigated the therapeutic combination of a CD30-targeting ADC (anti-CD30-lidamycin [LDM]) with a small-molecule inhibitor (crizotinib) of nucleophosmin-anaplastic lymphoma kinase NPM-ALK in CD30<sup>+</sup>/ALK<sup>+</sup> anaplastic large cell lymphoma (ALCL).
|
30742941 |
2019 |
|
Ki-1+ Anaplastic Large Cell Lymphoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
Our findings suggest that overexpression of c-FLIP protects ALK+ ALCL cells from death-receptor-induced apoptosis and may contribute to ALCL pathogenesis.
|
16304056 |
2006 |